ESTROGENIC ACTIVITY OF RU-486 (MIFEPRISTONE) IN RAT UTERUS AND CULTURED UTERINE MYOCYTES

被引:18
作者
DIBBS, KI
SADOVSKY, Y
LI, XJ
KOIDE, SS
ADLER, S
FUCHS, AR
机构
[1] WASHINGTON UNIV,SCH MED,DEPT OBSTET & GYNECOL,DIV MATERNAL FETAL MED,ST LOUIS,MO 63110
[2] POPULAT COUNCIL,CTR BIOMED RES,NEW YORK,NY 10021
[3] CORNELL UNIV,COLL MED,DEPT OBSTET & GYNECOL,NEW YORK,NY
关键词
RU; 486; ESTROGENIC ACTIVITY MYOCYTES; OVARIECTOMIZED RATS; OXYTOCIN RECEPTOR;
D O I
10.1016/0002-9378(95)90181-7
中图分类号
R71 [妇产科学];
学科分类号
100211 ;
摘要
OBJECTIVE: Our purpose was to determine whether RU 486 (mifepristone) has direct estrogenic activity in uterine myocytes. STUDY DESIGN: Ovariectomized adult rats were treated with RU 486, and its effect on uterine oxytocin receptor concentration, as a marker of estrogenic activity, was measured. Results were compared with the induction by RU 486 of an estrogen-responsive reporter gene in a cultured Syrian hamster uterine myocyte cell line. RESULTS: Baseline oxytocin receptor concentration was 58.8 +/- 7.2 fmol/mg protein (mean +/- SEM) and increased to 227 +/- 49 fmol/mg with 17 beta-estradiol (2.5 mu g/kg) and to 145 +/- 18 fmol/mg after RU 486 (5 mg/kg) treatment, an effect that was inhibited by the antiestrogen ICI 182,780 (1.5 mg/kg). In the cultured Syrian hamster uterine myocyte cell line cells RU 486 (10(-6) mol/L) caused a 2.17 +/- 0.17-fold increase in the expression of the reporter gene versus 113.0 +/- 7.4-fold with 17 beta-estradiol (10(-8) mol/L). The estrogenic activity of RU 486 was dependent on the presence of both estrogen receptor and the promoter's estrogen response element. CONCLUSION: RU 486 has a weak estrogen-like activity in uterine myocytes. This activity may partly explain the therapeutic effects of RU 486 on this target organ.
引用
收藏
页码:134 / 140
页数:7
相关论文
共 32 条
[1]   EFFECT OF THE ANTIGLUCOCORTICOID RU486 ON ADRENAL STEROIDOGENIC ENZYME-ACTIVITY AND STEROIDOGENESIS [J].
ALBERTSON, BD ;
HILL, RB ;
SPRAGUE, KA ;
WOOD, KE ;
NIEMAN, LK ;
LORIAUX, DL .
EUROPEAN JOURNAL OF ENDOCRINOLOGY, 1994, 130 (02) :195-200
[2]   TREATMENT OF BREAST-CANCER WITH DIFFERENT ANTIPROGESTINS - PRECLINICAL AND CLINICAL-STUDIES [J].
BAKKER, GH ;
SETYONOHAN, B ;
PORTENGEN, H ;
DEJONG, FH ;
FOEKENS, JA ;
KLIJN, JGM .
JOURNAL OF STEROID BIOCHEMISTRY AND MOLECULAR BIOLOGY, 1990, 37 (06) :789-794
[3]  
Baulieu E.E., 1985, ANTIPROGESTIN STEROI, P1
[4]   CONTRAGESTION AND OTHER CLINICAL-APPLICATIONS OF RU-486, AN ANTIPROGESTERONE AT THE RECEPTOR [J].
BAULIEU, EE .
SCIENCE, 1989, 245 (4924) :1351-1357
[5]   ROLE OF THE 2 ACTIVATING DOMAINS OF THE ESTROGEN-RECEPTOR IN THE CELL-TYPE AND PROMOTER-CONTEXT DEPENDENT AGONISTIC ACTIVITY OF THE ANTIESTROGEN 4-HYDROXYTAMOXIFEN [J].
BERRY, M ;
METZGER, D ;
CHAMBON, P .
EMBO JOURNAL, 1990, 9 (09) :2811-2818
[6]   PHENOL RED IN TISSUE-CULTURE MEDIA IS A WEAK ESTROGEN - IMPLICATIONS CONCERNING THE STUDY OF ESTROGEN-RESPONSIVE CELLS IN CULTURE [J].
BERTHOIS, Y ;
KATZENELLENBOGEN, JA ;
KATZENELLENBOGEN, BS .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1986, 83 (08) :2496-2500
[7]   ESTROGENIC EFFECTS OF THE ANTIPROGESTIN ONAPRISTONE (ZK98.299) IN THE RODENT UTERUS [J].
BIGSBY, RM ;
YOUNG, PCM .
AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY, 1994, 171 (01) :188-194
[8]   HIGH-EFFICIENCY TRANSFORMATION OF MAMMALIAN-CELLS BY PLASMID DNA [J].
CHEN, C ;
OKAYAMA, H .
MOLECULAR AND CELLULAR BIOLOGY, 1987, 7 (08) :2745-2752
[9]   OXYTOCIN AND VASOPRESSIN RECEPTORS IN BOVINE ENDOMETRIUM AND MYOMETRIUM DURING THE ESTROUS-CYCLE AND EARLY-PREGNANCY [J].
FUCHS, AR ;
BEHRENS, O ;
HELMER, H ;
LIU, CH ;
BARROS, CM ;
FIELDS, MJ .
ENDOCRINOLOGY, 1990, 127 (02) :629-636
[10]   ENDOMETRIAL AND PITUITARY RESPONSES TO THE STEROIDAL ANTIPROGESTIN RU-486 IN POSTMENOPAUSAL WOMEN [J].
GRAVANIS, A ;
SCHAISON, G ;
GEORGE, M ;
DEBRUX, J ;
SATYASWAROOP, PG ;
BAULIEU, EE ;
ROBEL, P .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 1985, 60 (01) :156-163